According to a report from Reuters, the US Federal Trade Commission (FTC) has sought additional information from Bristol-Myers Squibb and Celgene and is focusing on the companies’ psoriasis treatments as part of its review of their planned merger, Bristol-Myers announced on Tuesday, March 26.
“The parties understand that the FTC’s review is focused on marketed and pipeline products for the treatment of psoriasis,” Bristol-Myers stated in a filing.
Celgene’s psoriasis drug Otezla brought US$448 million in sales in the quarter ended December 31. Bristol-Myers is also developing a treatment for the condition and in September reported positive results from a mid-stage trial of its plaque psoriasis drug.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
